ArticleFrontiers in medicine2025
Time to viral load re-suppression and its predictors among adult patients on second-line anti-retro viral therapy in northeastern Ethiopia: multi-center prospective follow-up study.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- Developing a Naïve Bayes risk classification machine learning algorithm to predict high viral load in a low-resource setting.PLOS global public health · 2026Article
- Rate of Viral Resuppression and Predictors Among PLHIV on Second-Line Antiretroviral Therapy at Gondar Comprehensive Specialized Hospital, Northwest, Ethiopia: A Retrospective Cohort Study.Journal of the International Association of Providers of AIDS CareArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Despite the increasing number of patients on second-line antiretroviral therapy in low-income countries such as Ethiopia, there is limited evidence regarding the time to viral re-suppression. Therefore, this study aimed to assess the time to viral load re-suppression and its predictors among adult patients on second-line antiretroviral therapy in northeastern Ethiopia. Method: A multi-center, institution-based prospective follow-up study was conducted over 48 months, from February 2022 to February 2024, involving 526 adults living with human immunodeficiency virus (HIV) who were receiving second-line antiretroviral therapy in northeastern Ethiopia. Data were collected through face-to-face interviews and chart reviews. A Weibull proportional hazards model was fitted to identify the predictors of viral re-suppression. Results: The median time to viral re-suppression was 9 months (IQR = 3-15 months). The rate of viral re-suppression was 44.3 per 1,000 person-months (95% CI: 40.4-49). Predictors of viral re-suppression included disclosure of Human Immunodeficiency Virus (HIV) status [AHR 2.24 (95% CI: 1.4-3.7)], classification in World Health Organization (WHO) clinical stages I and II [AHR 6.9 (95% CI: 4.4-9.6)], receipt of tuberculosis (TB) preventive treatment [AHR 3.7 (95% CI: 2.3-5.93)], absence of first-line drug substitution history [AHR 1.44 (95% CI: 1.2-1.8)], and good adherence to treatment [AHR 1.9 (95% CI: 1.4-2.54)]. Conclusion and recommendations: In this study, the time to viral load re-suppression was longer than expected. Disclosure status, WHO clinical stage I or II, receiving tuberculosis preventive treatment, and the absence of first-line drug substitution history were predictors of viral load re-suppression. Health managers and antiretroviral therapy care providers must improve the timing and effectiveness of early disclosure, encourage the early use of tuberculosis prophylaxis, and maintain good adherence through various strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.